SkinHealth Systems Inc.
No SEC Form 4 filings for $SKIN in the last 30 days.
See all $SKIN insider activity →SkinHealth Systems (SKIN) repaid $103.2 million in 1.25% Convertible Senior Notes due 2026, plus $0.6 million in accrued interest, on Sep 30, 2026. The Indenture was discharged, simplifying the company's capital structure. No penalties or exit fees were incurred.
SkinHealth Systems Inc. (SKIN) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02. Termination of a Material Definitive Agreement. On September 30, 2026, the remaining outstanding aggregate principal amount of the 1.25% Convertible Senior Notes due 2026 (the “Notes”) issued by SkinHealth Systems Inc. (the “Company”), pursuant to the Indenture, dated
SkinHealth Systems (SKIN) has expanded its SkinStylus SteriLock MicroSystem, a professional microneedling and nano-needling device, to Europe. The launch includes the UK, Ireland, Germany, France, Spain, and Portugal, leveraging the company's existing Hydrafacial commercial network. The expansion aims to broaden SkinHealth Systems' medical aesthetics ecosystem and offer complementary solutions for various skin concerns.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning SKIN (SkinHealth Systems Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent SKIN coverage spans corporate actions, financial news and technology.
Debt reduction improves balance‑sheet strength and may modestly support the stock.
Debt retirement improves balance sheet and reduces interest expense.
The expansion adds a new revenue stream but is limited to a niche aesthetic market.
The approved reverse split will reduce share count and may improve price perception, but could also trigger short covering or sell pressure.
Positive trial data may boost demand for the company's aesthetic platforms and support near‑term price appreciation.
AlphAI scores every news story that mentions SKIN with an AI model for sentiment and relevance, and aggregates insider trades from SkinHealth Systems Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
SkinHealth Systems (SKIN) repaid $103.2 million in 1.25% Convertible Senior Notes due 2026, plus $0.6 million in accrued interest, on Sep 30, 2026. The Indenture was discharged, simplifying the company's capital structure. No penalties or exit fees were incurred.
1 min readSkinHealth Systems Inc. (SKIN) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02. Termination of a Material Definitive Agreement. On September 30, 2026, the remaining outstanding aggregate principal amount of the 1.25% Convertible Senior Notes due 2026 (the “Notes”) issued by SkinHealth Systems Inc. (the “Company”), pursuant to the Indenture, dated
1 min readSkinHealth Systems (SKIN) has expanded its SkinStylus SteriLock MicroSystem, a professional microneedling and nano-needling device, to Europe. The launch includes the UK, Ireland, Germany, France, Spain, and Portugal, leveraging the company's existing Hydrafacial commercial network. The expansion aims to broaden SkinHealth Systems' medical aesthetics ecosystem and offer complementary solutions for various skin concerns.
2 min readSkinHealth Systems Inc. (SKIN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 22, 2026, SkinHealth Systems Inc., a Delaware corporation (the “Company”), held its previously disclosed 2026 special meeting of stockholders (the “Special Meeting”) in a virtual format. At the close of
1 min readSkinHealth Systems (SKIN) announced clinical data on HydraScalp and Hydrafacial treatments, showing improvements in scalp and skin health. Studies found significant benefits, including increased hydration and reduced dandruff for HydraScalp, and enhanced skin quality for Hydrafacial. The company will present findings at the 2026 Science of Skin Summit. SKIN's stock is currently at $0.70, up 0.04%.
2 min readSkinHealth Systems Inc. (SKIN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective September 3, 2026, the Board of Directors of SkinHealth Systems Inc. (the “Company”) promoted its Chief Financia
1 min readSkinHealth Systems Inc. (SKIN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Operating Officer Departure On August 10, 2026, Sheri Lewis notified SkinHealth Systems Inc. (the “Company”) of her
3 min readSkinHealth Systems Inc. (SKIN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SkinHealth Systems Reports Second Quarter 2026 Financial Results Long Beach, Calif., August 6, 2026 – SkinHealth Systems Inc. (NASDAQ: SKIN) (“SkinHealth Systems” or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the second
6 min readSkinHealth Systems (NASDAQ: SKIN) said the FDA cleared its SkinStylus SteriLock microneedling device to improve periorbital wrinkles in adults 22+ for all Fitzpatrick skin types. The clearance expands indications to include facial acne scars and abdominal hypertrophic scars. The company cited 2025 U.S. microneedling spend of about $330M (+33% YoY) and noted Hydrafacial pairing interest.
4 min readSkinHealth Systems Inc. (SKIN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. skin-20260610 FALSE 0001818093 Nasdaq 0001818093 2026-06-10 2026-06-10 0001818093 us-gaap:CommonStockMember 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exch
2 min read
